A Phase 2 Study of OBE001 Versus Placebo in the Delay of Preterm Birth (TERM)
A Phase 2, Double-blind, Parallel Group, Randomised, Placebo Controlled, Proof of Concept Study to Assess the Safety and Efficacy of OBE001 After Oral Administration in Pregnant Women With Threatened Preterm Labour.
Sponsor: ObsEva SA
Terminated
Enrolment difficulties.
Other Preterm Labor trials with similar outcome
Listed as NCT02326142, this PHASE2 trial focuses on Preterm Labor and remains terminated or withdrawn. Sponsored by ObsEva SA, it has been updated 8 times since 2015, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 3 earlier versions
-
Dec 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Feb 2017 — Dec 2017 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Mar 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- ObsEva SA
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Barcelona, Spain , Basel, Switzerland , Bayreuth, Germany , Bern, Switzerland , Bialystok, Poland , Brussels, Belgium , Chorzów, Poland , Düsseldorf, Germany , El Palmar, Spain , Geneva, Switzerland and 13 more locations